Rx Radar · Open for comment
Peptides: the October 28 policy
For years, BPC-157 and peptides like it lived on research-chemical sites. On October 28, 2026, HHS opened a path through licensed prescribers and 503A compounding pharmacies, under specific conditions. The door is open. The research hasn't caught up, and the rule isn't final.
Settled, for now
- Licensed 503A pharmacies may compound BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon for a patient-specific prescription, under the policy's conditions.
- BPC-157 is covered as an injection (under the skin or into muscle), oral, or topical. Each peptide has its own listed routes.
- One active ingredient only. Blends like BPC-157 + TB-500 are not covered.
- The bulk ingredient must come from an FDA-registered facility with a valid certificate of analysis.
- Research-use-only vials are not covered, and none of these peptides is FDA approved.
Still moving
- Public comments are open through November 13, 2026.
- The policy has no end date, but HHS says it can revisit it if a safety or quality problem appears.
- Human evidence is still limited. Most published BPC-157 research is in animals.
The timeline
The story so far.
Newest first. Every entry is dated and sourced, and nothing is edited after the fact.
Public comment period on the peptide policy closes.
DataMEDS (NASDAQ: MEDS) says its Corexa Pharmacy plans to begin dispensing compounded prescriptions for all six peptides in November 2026.
Policy takes effect. HHS will not take action against qualifying 503A pharmacies, federal facilities and licensed physicians compounding the six peptides under its conditions.
HHS announces enforcement discretion for BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon.
Day two of the advisory meeting: the committee recommends Semax and Epitalon.
FDA's Pharmacy Compounding Advisory Committee votes 8 to 6, with one abstention, to recommend adding BPC-157 to the 503A Bulks List. FDA's own reviewers had advised against it.
The tracker
BPC-157 provider tracker.
Who offers it, and what they tell you before you pay. A provider is named here only after we confirm on its own website that it offers BPC-157. Then it's checked against the same six questions as every company in the Disclosure Index.
6 more providers spotted on third-party lists. Each gets named here once we've confirmed it on the company's own site.
Pharmacies
Listed only when a pharmacy has publicly announced it, or a provider names it.
† Televetted may earn a commission if you sign up with this provider. It never changes what we report or any score.
Go deeper
The deep dives.
Rx Radar reports what has been announced and where it came from. It is not medical advice, and nothing here means a treatment is right for you. A licensed clinician makes that call.